Laura Panjwani


Expert Discusses Promise of Quizartinib in AML

March 15th 2017

Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.

Pan-Kinase Inhibition Key to Midostaurin Benefit in AML

March 7th 2017

FLT3 targeted agents are emerging in the treatment of acute myeloid leukemia, and which specific agent will be most effective is highly dependent on whether a patient has been previously treated.

Immunotherapy Makes Comeback in RCC, But Challenges Remain

December 6th 2016

Robert G. Uzzo, MD, discusses the promise of immunotherapies as well as the challenges with using them across different indications in renal cell carcinoma.

Tumor-Treating Fields Make Significant Impact in GBM

December 1st 2016

It’s not often that oncologists get to be the first to utilize cutting-edge technology.

Immunotherapy Combos on Horizon in First-Line RCC

December 1st 2016

Immunotherapy combinations have significant potential as treatment for patients with renal cell carcinoma.

Third-Generation TKI Most Promising Option for Ph+ ALL

November 30th 2016

Tyrosine-kinase inhibitors have considerably improved survival outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Lead PALOMA-2 Author Says Results Will Boost Global Use of Palbociclib

November 28th 2016

Results from the phase III PALOMA-2 study—which demonstrated a significant progression-free survival advantage with palbociclib (Ibrance) plus letrozole compared with letrozole alone in ER-positive, HER2-negative metastatic breast cancer—were recently published in The New England Journal of Medicine.

Investigating EGFR Resistance Leads to New Therapies, Advances in NSCLC

November 23rd 2016

While resistance to EGFR-targeted therapies in non–small cell lung cancer presents a major challenge, there is a silver lining.

I-SPY 2 Paves the Way for Novel HER2-Targeted Agents in Breast Cancer

November 22nd 2016

There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.

Cetuximab Benefit, Tumor Sidedness Impact Still Unclear in mCRC

November 21st 2016

Alan P. Venook, MD, discusses key issues in metastatic colorectal cancer, including tumor sidedness and the conflicting data regarding the precise benefit of cetuximab in the frontline setting.